<DOC>
	<DOCNO>NCT01593228</DOCNO>
	<brief_summary>The purpose study assess safety tolerability iniparib administer monotherapy combination regimens patient previously treat iniparib clinical study derive clinical benefit completion parental study 's objective .</brief_summary>
	<brief_title>Treatment Extension Study Patients Who Have Previously Participated Have Benefited From Iniparib Clinical Trial</brief_title>
	<detailed_description>The Treatment Extension protocol consist three time points/periods : Screening Period ( assessment perform determine whether patient meet criteria participate study ) , Treatment Period ( patient receive treatment study drug ( ) ) , Post-Treatment Period ( patient complete evaluation approximately 30 day last dose study drug ) . Patients may continue participate Treatment Extension study long meet criterion continue receive therapy , tolerate treatment regimen , develop progressive disease ( PD ) , discontinue iniparib , withdraw consent , iniparib becomes commercially available .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Iniparib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Inclusion criterion : Cancer patient great 18 year age complete assessment require meet primary objective parental phase 1 , 2 3 clinical study iniparib monotherapy combination regimen . Previously receive continue derive clinical benefit iniparib , monotherapy combination chemotherapy , determine treat physician . Ongoing treatment iniparib time parental study completion/closure meet criterion initiate subsequent cycle therapy , describe parental study protocol . On stable parental study regimen ( least one cycle regimen dose/schedule give Treatment Extension study must give prior patient 's discontinuation parental study ) . Signed write informed consent . Exclusion criterion : Patient previously participate clinical trial iniparib . Patient evidence progressive disease receive iniparib . Patient another concurrent invasive malignancy ( aside malignancy patient receive therapy parental protocol ) . Patient major medical comorbid condition ( ) investigator believe might compromise safe participation study ( uncontrolled lung , kidney , liver problem ; uncontrolled infection ; history congestive heart failure ; electrocardiogram suggest significant problem heart ) . Patient recover baseline less Grade 1 nonhematologic adverse event related anticancer therapy receive prior sign informed consent Treatment Extension study , exception hair loss . Patient receive concurrent treatment investigational agent allow part combination regimen parental study protocol . Concurrent anticancer treatment agent iniparib coadministered chemotherapeutic agent ( ) specify parental study protocol permit throughout course study . Patient receive concurrent radiation therapy treat primary disease curative intent . ( Note palliative radiotherapy allow long evidence progressive disease . ) Patient unable comply requirement study . Pregnant breastfeed woman . Women childbearing potential men partner childbearing potential protect unwilling use effective contraceptive method birth control course study period 6 month follow last dose . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>